Results 61 to 70 of about 134,036 (314)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension

Vascular Health and Risk Management, 2007
John D Bisognano1, Trent McLaughlin2, Craig S Roberts3, Simon SK Tang31Internal Medicine Department, Cardiology Division, the University of Rochester Medical Center, Rochester, NY, USA; 2NDC Health, Phoenix, Arizona, USA; 3Pfizer Inc, New York, NY ...
John D Bisognano, Trent McLaughlin, Craig S Roberts, Simon SK Tang   +3 more
doaj  

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

IRBESARTAN IN THE CLINICAL PRACTICE

Рациональная фармакотерапия в кардиологии, 2015
Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal ...
V. I. Podzolkov, A. I. Tarzimanova
doaj   +3 more sources

Effect of ACE Inhibitors, ARBs, and Other Antihypertensive Drugs on Hypertensive Patients with COVID-19 Infection

Novelty in Biomedicine
Background: To investigate differences in disease severity and outcomes among COVID-19 patients with a history of hypertension using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other antihypertensive drugs.
Seyedpouzhia Shojaei, Sara Nooraeen, Zahra Soroureddin, Meghdad Sedaghat, Padideh Ansar, Sadaf Rassouli, Mehdi Goudarzi, Mehrdad Haghighi   +7 more
doaj   +1 more source

Angiotensin AT1–Receptor Blockers Enhance Cardiac Responses to Parasympathetic Nerve Stimulation via Presynaptic AT1 Receptors in Pithed Rats

Journal of Pharmacological Sciences, 2013
.: In the present study, we investigated the effects of angiotensin AT1–receptor blockers, KT3-671 and losartan, on the cardiac vagal neurotransmission in pithed rats.
Fumiko Yamaki, Takanori Arai, Masato Aoyama, Akane Watanabe, Yoshinobu Takata   +4 more
doaj   +1 more source

Effects of Antihypertensive Drugs on Thyroid Function in Type 2 Diabetes Patients With Euthyroidism

Frontiers in Pharmacology, 2022
Objective: There is little literature about whether antihypertensive drugs would affect thyroid function in patients with euthyroid type 2 diabetes, which was significant in maintaining a proper balance of thyroid function.
Lijuan Yang, Xiuqin Sun, Yi Zhao, Hong Tao   +3 more
doaj   +1 more source

Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction [PDF]

, 2011
<b>Background</b> Meta-analysis of small trials suggests that pharmacist-led collaborative review and revision of medical treatment may improve outcomes in heart failure.<p></p> <b>Methods and results</b> We studied
Forsyth, P., Greenlaw, N., Jhund, P.S., Lowrie, R., Mair, F.S., McConnachie, A., McMurray, J.J.V., Rae, B.   +7 more
core   +1 more source

Angiotensin II receptor pharmacology and AT1-receptor blockers [PDF]

Journal of Human Hypertension, 1999
Angiotensin II (Ang II) has diverse physiological actions leading, for example, to increases in extracellular volume, peripheral vascular resistance and blood pressure, and has also been implicated in the regulation of cell growth and differentiation.
O, Chung, T, Csikós, T, Unger
openaire   +2 more sources

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

Advanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang, Wing Yan Chung, Serena M. Pulente, Yubin Lei, Khang Nguyen, Eddie Tam, Nadya M. Morrow, Ilka Lorenzen‐Schmidt, Fengxia Xiao, Augusto Zani, Dylan Burger, Hye Kyoung Sung, Erin E. Mulvihill, Gary Sweeney   +13 more
wiley   +1 more source